Scottsdale TMS Therapy, a mental health clinic in Scottsdale, Arizona, has expanded its interventional psychiatry offerings by introducing FDA-approved Spravato (esketamine) nasal spray treatments for adults with treatment-resistant depression. The addition addresses a critical gap in care for patients who experience limited relief from conventional oral antidepressants, which typically require four to six weeks to produce measurable effects.
Esketamine therapy works through a distinct mechanism, targeting NMDA receptors in the brain to promote neuroplasticity—the formation of new neural connections that support emotional regulation. This fast-acting approach can reduce depressive symptoms and suicidal ideation within days, providing an immediate lifeline for individuals who have not responded to two or more standard antidepressant trials. The clinic pairs this treatment with existing transcranial magnetic stimulation (TMS) protocols to address the biological underpinnings of major depressive disorder at a foundational level.
“When standard medications fail to deliver remission, it is an indication that the underlying neural networks require a different mechanism of stimulation,” stated a spokesperson for Scottsdale TMS Therapy. “Spravato represents a major milestone in complex mood disorder care. Because it can reduce persistent depressive symptoms and decrease suicidal ideation within days rather than weeks, it serves as an immediate lifeline that restores cognitive flexibility and prepares patients for long-term psychological stabilization.”
As a tightly regulated medication, esketamine requires structured medical administration. Scottsdale TMS Therapy operates as a fully REMS-certified clinic, satisfying all applicable federal safety and monitoring standards. Under the supervision of board-certified psychiatrists and master’s-level clinicians, each outpatient session includes pre-treatment health screenings, supervised self-administration, and a mandatory two-hour post-treatment observation period during which blood pressure and vital signs are continuously monitored.
This structured medical oversight is provided within a private, comfort-focused setting designed to minimize patient stress and support emotional safety. The Scottsdale facility features Apollo TMS chairs, private treatment rooms, an on-site cafe, and an outdoor patio. To support broad access, the clinic works with major commercial payors and accepts most insurance plans, managing the full authorization process internally.
The implications of this announcement are significant for the estimated 30% of patients with major depressive disorder who do not achieve remission with traditional treatments. By offering an evidence-supported, fast-acting option, the clinic provides a meaningful alternative that can reduce the psychological burden of prolonged medication adjustments. For individuals caught in a cycle of pharmaceutical trials, esketamine therapy may restore cognitive flexibility and enable long-term stabilization. The clinic’s integration of multiple interventional modalities—TMS and esketamine—positions it as a comprehensive resource for complex mood disorders in the Southwest.
Individuals or family members seeking guidance on interventional options for severe major depressive disorder can contact the clinical admissions team at Scottsdale TMS Therapy for confidential consultations, diagnostic evaluations, and same-day insurance verification to support immediate placement.
